
iRhythm Technologies (IRTC) Stock Forecast & Price Target
iRhythm Technologies (IRTC) Analyst Ratings
Bulls say
iRhythm Holdings is in a strong position for sustained growth with their successful acquisitions and expected potential for expanding margins and reaching a high stock price. As their proprietary platform becomes the standard for outpatient cardiac monitoring and they continue to expand into other markets, there is a strong potential for continued revenue growth. However, risks such as legal and operational challenges, as well as competition, should be monitored carefully.
Bears say
iRhythm Holdings is maintaining strong revenue and earnings growth, with expected continued improvement due to continued scale and disciplined expense management. Despite a recent FDA clearance for their Gen 3 algorithm, it will not be implemented until 1H27, limiting its potential impact on cutting technician review time. Additionally, while the company's top priority is its Zio MCT device, it has faced delays and challenges with FDA submission and addressing cybersecurity concerns.
This aggregate rating is based on analysts' research of iRhythm Technologies and is not a guaranteed prediction by Public.com or investment advice.
iRhythm Technologies (IRTC) Analyst Forecast & Price Prediction
Start investing in iRhythm Technologies (IRTC)
Order type
Buy in
Order amount
Est. shares
0 shares